X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs CIPLA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA CIPLA AUROBINDO PHARMA/
CIPLA
 
P/E (TTM) x 18.0 44.1 40.8% View Chart
P/BV x 5.8 3.6 160.8% View Chart
Dividend Yield % 0.4 0.4 100.4%  

Financials

 AUROBINDO PHARMA   CIPLA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-16
CIPLA
Mar-17
AUROBINDO PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,541622 247.7%   
Low Rs582458 127.0%   
Sales per share (Unadj.) Rs237.5181.9 130.6%  
Earnings per share (Unadj.) Rs33.912.9 263.2%  
Cash flow per share (Unadj.) Rs40.629.3 138.4%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.20.4 63.6%  
Book value per share (Unadj.) Rs120.6155.7 77.5%  
Shares outstanding (eoy) m585.17804.51 72.7%   
Bonus/Rights/Conversions PREFESOP-  
Price / Sales ratio x4.53.0 150.5%   
Avg P/E ratio x31.342.0 74.7%  
P/CF ratio (eoy) x26.218.4 141.9%  
Price / Book Value ratio x8.83.5 253.7%  
Dividend payout %7.415.5 47.5%   
Avg Mkt Cap Rs m621,041434,516 142.9%   
No. of employees `00013.323.0 57.7%   
Total wages/salary Rs m15,50826,338 58.9%   
Avg. sales/employee Rs Th10,457.66,349.1 164.7%   
Avg. wages/employee Rs Th1,167.11,143.0 102.1%   
Avg. net profit/employee Rs Th1,491.6449.3 331.9%   
INCOME DATA
Net Sales Rs m138,961146,302 95.0%  
Other income Rs m1,6632,287 72.7%   
Total revenues Rs m140,624148,589 94.6%   
Gross profit Rs m32,05624,758 129.5%  
Depreciation Rs m3,92613,229 29.7%   
Interest Rs m2,5681,594 161.1%   
Profit before tax Rs m27,22512,222 222.8%   
Minority Interest Rs m390-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,4441,798 414.1%   
Profit after tax Rs m19,82010,354 191.4%  
Gross profit margin %23.116.9 136.3%  
Effective tax rate %27.314.7 185.9%   
Net profit margin %14.37.1 201.5%  
BALANCE SHEET DATA
Current assets Rs m100,01587,370 114.5%   
Current liabilities Rs m74,75933,081 226.0%   
Net working cap to sales %18.237.1 49.0%  
Current ratio x1.32.6 50.7%  
Inventory Days Days10787 123.5%  
Debtors Days Days11062 175.9%  
Net fixed assets Rs m52,350111,567 46.9%   
Share capital Rs m5851,609 36.4%   
"Free" reserves Rs m67,707123,645 54.8%   
Net worth Rs m70,567125,254 56.3%   
Long term debt Rs m8,47236,454 23.2%   
Total assets Rs m156,994209,532 74.9%  
Interest coverage x11.68.7 133.9%   
Debt to equity ratio x0.10.3 41.3%  
Sales to assets ratio x0.90.7 126.8%   
Return on assets %14.35.7 250.1%  
Return on equity %28.18.3 339.8%  
Return on capital %37.78.5 444.0%  
Exports to sales %51.034.2 149.2%   
Imports to sales %18.88.3 226.0%   
Exports (fob) Rs m70,92750,050 141.7%   
Imports (cif) Rs m26,19312,203 214.6%   
Fx inflow Rs m71,01551,066 139.1%   
Fx outflow Rs m28,79917,678 162.9%   
Net fx Rs m42,21633,388 126.4%   
CASH FLOW
From Operations Rs m17,59623,824 73.9%  
From Investments Rs m-13,801-13,127 105.1%  
From Financial Activity Rs m-198-13,239 1.5%  
Net Cashflow Rs m3,597-2,478 -145.1%  

Share Holding

Indian Promoters % 54.1 16.0 338.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 8.0 12.2 65.2%  
FIIs % 27.7 23.7 116.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.2 26.2 38.9%  
Shareholders   69,601 161,166 43.2%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS